It's time for investors to watch Oramed Pharmaceuticals Inc. (OTCBB: ORMP) again. Yesterday the company, focused on the development of oral delivery solutions, issued a press release announcing that it is beginning additions to an Advisory Board, by adding Dr. Harold Jacob.

This should be a great addition for the company. Dr. Jacob is president of Medical Instrument Development Inc., which is a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting its own proprietary medical devices and biologicals.

Dr. Harold Jacob has a strong background, both in medical sciences as well as biotechnology and medical devices. He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. Johns Episcopal Hospital and South Nassau Communities Hospital, and was a Clinical Assistant Professor of Medicine at SUNY. Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology.

Continue to watch this company. CEO Nadav Kidron states, "We are honored to have Dr. Harold Jacob advise us, and look forward to working with him to complete development of the our oral insulin, which will simplify the lives of millions of diabetics and realize the immense growth potential that Oramed holds."

The ability to correctly self-administer doses of insulin is crucial to the long-term health of diabetics. For years, the only method patients had to deliver insulin to their bodies was by injection. Oramed's highly respected team of scientists discovered a technology at the Hadassah University Hospital that has the potential to change all of that.

Stock Market Alerts first initiated coverage of the company last month, when it announced its 1-year anniversary and accomplishments. At that time, the CEO stated that the company had surpassed the International Review Board and Ministry of Health approvals to further its initial flagship product, oral insulin, toward human clinical trials and that it had also gained the support of Swiss Caps, one of the largest manufacturers of soft gel capsules in the world.

In December, During Oramed's presentation at the Wall Street Analyst Forum, Dr. Miriam Kidron, Oramed's Chief Technology Officer, was asked to comment on the comparison of Oramed's insulin capsule versus an insulin inhaler. Dr. Kidron responded, "There is no comparison. The inhaler was designed in an effort to mimic the effects of subcutaneous insulin, which is not physiologically natural. Insulin should not be delivered directly into the bloodstream. Oramed's capsule provides a better physiological entry for insulin." Dr. Kidron was asked if she thought that diabetics were afraid to take the needle. To that question she responded, "Some diabetics may be fearful of the needles, but millions are injecting themselves daily, including some who inject multiple times daily. The significance of Oramed's insulin differentiates it from the rest of the insulin products because it administers the insulin to the body via the portal vein, which then supplies the liver with insulin rather than directly to the bloodstream.

ORMP stock closed Tuesday at Seventy cents a share.

For Stock Market Alert's in-depth and updated profile of Oramed Pharmaceuticals, visit http://www.WallStreetENews.com/HotStocks/ORMP041007/default.aspx

Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.

Other Stocks of interest yesterday were:

Dendreon Corporation (NASDAQ: DNDN) down 6% on 66.8 million shares traded. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Adolor Corporation (NASDAQ: ADLR) down 58.7% on 28.2 million shares traded. Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Amgen (NASDAQ: AMGN) down 0.1% on 11.9 million shares traded. Amgen discovers, develops and delivers innovative human therapeutics.

Wall Street Enews is a Sponsor of Quality Stocks. Quality Stocks tracks the stock picks of 150 Investment Newsletters every day and reports on their performance. For Their Free Service, Visit www.qualitystocks.net.

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company received compensation for services performed for Oramed Pharmaceuticals Inc. (OTCBB: ORMP). The compensation is twenty five thousand dollars in 2007 (twelve thousand dollars for previous advertising and thirteen thousand for current advertising) from third party, Alex Consulting Inc., who is non-affiliated and may hold a significant position in the stock. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.

The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.

This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.